Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mecasermin rinfabate - Takeda

Drug Profile

Mecasermin rinfabate - Takeda

Alternative Names: HGT-ROP-001; IGF-I/IGFBP-3; Insulin-like growth factor-I/insulin-like growth factor binding protein-3; IPLEX; Mecasermin rinfabate; Premiplex; rhIGF-I/rhIGFBP-3; SHP607; SomatoKine; Somatomedin-C/Somatomedin-1-binding-protein-3; TAK 607

Latest Information Update: 15 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Insmed
  • Developer Insmed; Takeda
  • Class Antihyperglycaemics; Eye disorder therapies; Growth factors; Osteoporosis therapies
  • Mechanism of Action Insulin like growth factor binding protein 3 stimulants; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Insulin resistance; Growth disorders; Retinopathy of prematurity; Muscular dystrophies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lung disorders; Retinopathy of prematurity
  • Market Withdrawal Growth disorders
  • Suspended Muscular dystrophies
  • No development reported Amyotrophic lateral sclerosis
  • Discontinued Burns; Fracture; Insulin resistance; Lipodystrophy; Postmenopausal osteoporosis; Short stature; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 24 Jun 2018 Biomarkers information updated
  • 28 Feb 2018 Phase-II clinical trials in Lung disorders (Prevention, In neonates) in USA (IV) (Shire pipeline, February 2018) (NCT03253263)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top